Asta Juzeniene

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [212Pb]Pb-FAPI-46.

A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [212Pb]Pb-FAPI-46.

Journal: EJNMMI radiopharmacy and chemistry

Published: January 26, 2026

Radiobiological investigations of a [212Pb]Pb-carbonic anhydrase IX-targeting small-molecule ligand in renal cell carcinoma and colorectal cancer models.

Radiobiological investigations of a [212Pb]Pb-carbonic anhydrase IX-targeting small-molecule ligand in renal cell carcinoma and colorectal cancer models.

Journal: International journal of radiation biology

Published: January 02, 2026

Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001.

Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001.

Journal: Scientific reports

Published: July 11, 2025

Cytotoxicity of 212Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models.

Cytotoxicity of 212Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models.

Journal: EJNMMI radiopharmacy and chemistry

Published: July 10, 2025

Optimizing [212Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts.

Optimizing [212Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 20, 2025

Combination of PSMA targeting alpha-emitting radioligand [212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models.

Combination of PSMA targeting alpha-emitting radioligand [212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models.

Journal: Medical oncology (Northwood, London, England)

Published: April 02, 2025

Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.

Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 18, 2025

Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy.

Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy.

Journal: Molecular cancer therapeutics

Published: November 22, 2024

Antigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma.

Antigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma.

Journal: Scientific reports

Published: June 20, 2024

Exploring the Impact of mRNA Modifications on Translation Efficiency and Immune Tolerance to Self-Antigens.

Exploring the Impact of mRNA Modifications on Translation Efficiency and Immune Tolerance to Self-Antigens.

Journal: Vaccines

Published: May 06, 2024

Imaging of 212Pb in mice with a clinical SPECT/CT.

Imaging of 212Pb in mice with a clinical SPECT/CT.

Journal: EJNMMI physics

Published: March 07, 2023

Editorial: Targeted alpha particle therapy in oncology.

Editorial: Targeted alpha particle therapy in oncology.

Journal: Frontiers in medicine

Published: February 14, 2023

Showing 1-12 of 70

Last Updated: 09/26/2026